Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1049 | 1299 | 1164 | 868 | 1283 | 1429 |
Fund Return | 4.88% | 29.88% | 16.35% | -4.6% | 5.11% | 3.64% |
Place in category | 9 | 51 | 27 | 73 | 65 | 59 |
% in Category | 2 | 20 | 11 | 43 | 41 | 66 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Technology Fund I acc USD | 1.06B | 11.94 | 4.61 | 17.28 | ||
Franklin Technology Fund Z acc USD | 27.38M | 19.48 | -0.31 | 17.28 | ||
Franklin Technology Fund N acc USD | 388.51M | 3.70 | 1.34 | 15.32 | ||
Franklin Technology Fund W acc USD | 440.1M | 3.87 | 3.04 | 17.18 | ||
Franklin Technology Fund X acc USD | 7.25M | 3.92 | 3.82 | 18.08 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Equities L Biotechnology Class I US | 1.41B | 12.01 | 4.82 | 6.85 | ||
Equities L Biotechnology Class R US | 1.41B | 12.65 | 5.83 | 7.34 | ||
Candriam Equities Biotech C USD Cap | 1.68B | 11.83 | 4.94 | 6.48 | ||
LU0133359157 | 1.41B | 11.48 | 4.52 | 6.01 | ||
Pictet Biotech PUSD | 1.61B | 7.14 | -0.28 | 3.73 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Amgen | US0311621009 | 8.72 | 289.90 | +0.71% | |
Regeneron Pharma | US75886F1075 | 6.96 | 744.50 | +0.15% | |
Vertex | US92532F1003 | 6.08 | 450.37 | -0.19% | |
Ascendis Pharma AS | US04351P1012 | 3.86 | 122.64 | -1.40% | |
Gilead | US3755581036 | 3.68 | 89.76 | +1.27% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Buy |
Technical Indicators | Strong Sell | Sell | Strong Buy |
Summary | Strong Sell | Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review